Opinion
Video
Author(s):
Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
PACE-B trial: Five-fraction SBRT noninferior to conventional radiotherapy in prostate cancer
Dr. Murphy on increasing diversity in cancer clinical trials
Lisa F. Newcomb, PhD, on active surveillance for prostate cancer
Dr. Schwen on focal therapies for prostate cancer
Talazoparib/enzalutamide significantly boosts OS in mCRPC
Phase 1 data show encouraging safety of 177Lu-rhPSMA-10.1 injection in mCRPC